Ivermectin

Ivermectin's legitimate record is extraordinary: derived from a soil bacterium found near a Japanese golf course, it earned its discoverers the 2015 Nobel Prize and, through the Mectizan Donation Program running since 1987, has been distributed over four billion times — driving river blindness (onchocerciasis) out of most of the Americas and large parts of Africa, and forming half of the elimination strategy against lymphatic filariasis. It remains a WHO essential medicine for parasitic disease and a first-line scabies treatment. Any account of ivermectin that omits this history misses why hundreds of millions of people, particularly across Africa and Latin America, know the name as a benevolent one — soil the COVID claims grew in.

The story began legitimately: an April 2020 Australian laboratory study showed ivermectin killed SARS-CoV-2 in cell culture — at concentrations roughly 50-100 times what safe human dosing achieves in plasma, a caveat present in the paper and absent from its virality. Early meta-analyses then showed dramatic benefits, but they leaned on studies that collapsed under scrutiny — most notoriously the Elgazzar preprint, withdrawn amid evidence of data fabrication, whose removal alone erased much of the pooled effect. When the large, rigorous randomised trials reported — TOGETHER, ACTIV-6, PRINCIPLE — the answer converged on no meaningful clinical benefit, and Cochrane's review concluded likewise. This is the scientific method functioning correctly; the belief simply declined to update with it.

Ivermectin became an identity marker rather than a hypothesis: cheap, off-patent, and framed as the suppressed alternative to expensive novel drugs and vaccines — a narrative with built-in immunity to contrary trials, since every negative result reads as further suppression. Prescriptions in the US surged 24-fold above baseline in August 2021, poison-control calls climbed with veterinary-formulation use, and the conspiracy framing hardened when health agencies responded with mockery (the FDA's 'you are not a horse' post, later deleted as part of a legal settlement) rather than engagement. The episode is now a standard case study in how communication failures can entrench exactly the belief they target.

The pandemic ended; the movement did not. Beginning in 2025, several US states — Idaho, Arkansas and Tennessee among the first — enacted laws making ivermectin available over the counter without prescription, legislation explicitly framed as vindication rather than pharmacology. Meanwhile the same channels now promote ivermectin, often bundled with the veterinary anthelmintic fenbendazole, as a suppressed cancer cure — extrapolating from early-stage laboratory studies of antitumour mechanisms that exist for hundreds of compounds and have produced no controlled human evidence of benefit. Oncologists report patients delaying or abandoning effective treatment for antiparasitic protocols, which is where a mostly self-limiting belief becomes lethal.

Intellectual honesty requires stating what remains open: ivermectin research continues legitimately in parasitology (resistance monitoring, mass-administration strategies, new indications like malaria vector control, where ivermectin-treated humans and livestock kill the mosquitoes that bite them — a genuinely promising research line). Early-stage oncology screening of ivermectin alongside thousands of other compounds is normal science, not suppression. What is not open, on current evidence: clinical benefit in COVID-19, and cancer-cure claims in humans. A drug can be a masterpiece in its lane and a nullity outside it; ivermectin is the type specimen.

For parasitic disease, ivermectin is superb and its global-health record nearly unmatched. For COVID-19, the largest and best trials found no meaningful benefit, and no major guideline recommends it. For cancer, there is no controlled human evidence — and substituting it for effective oncology is the single most dangerous act in this entire story. Veterinary formulations are dosed for animals weighing half a tonne and have put people in hospital. And over-the-counter status, where legislatures have granted it, changes the law, not the pharmacology: availability is not evidence, in either direction.